Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
114 hedge funds and large institutions have $580M invested in Accelerate Diagnostics in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 12 closing their positions.
77% more capital invested
Capital invested by funds: $327M → $580M (+$253M)
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
34% more call options, than puts
Call options by funds: $17M | Put options by funds: $12.7M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
7% more funds holding
Funds holding: 107 → 114 (+7)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.81M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$5.59M |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$5.11M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.15M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$2.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$8.63M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$5.64M |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$5.11M |
| 4 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$3.23M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.8M |
AXDX Hedge Fund Activity: Q1 2019 in Review
114 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2019, worth a combined $580M — up 77% from $327M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AXDX positions and 12 closed out — a net gain of 8 holders — while 30 added to existing stakes and 32 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.81M. The largest seller was Amundi Asset Management US, cutting an estimated $8.63M.
- 114 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2019, up from 107 in Q4 2018.
- Funds reported $580M of Accelerate Diagnostics stock for Q1 2019, up 77% quarter-over-quarter.
- 20 funds opened new Accelerate Diagnostics positions in Q1 2019 and 12 closed out, a net change of +8 holders.
- The largest Accelerate Diagnostics buyer in Q1 2019 was Morgan Stanley, an estimated $5.81M added.
- The largest Accelerate Diagnostics seller in Q1 2019 was Amundi Asset Management US, an estimated $8.63M sold.
Based on aggregated 13F filings for Q1 2019.